GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Asset Turnover

HLTRF (HLS Therapeutics) Asset Turnover : 0.09 (As of Dec. 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. HLS Therapeutics's Revenue for the three months ended in Dec. 2024 was $15.54 Mil. HLS Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $165.82 Mil. Therefore, HLS Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. HLS Therapeutics's annualized ROE % for the quarter that ended in Dec. 2024 was -16.05%. It is also linked to ROA % through Du Pont Formula. HLS Therapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -7.29%.


HLS Therapeutics Asset Turnover Historical Data

The historical data trend for HLS Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Asset Turnover Chart

HLS Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.21 0.24 0.28 0.31

HLS Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.06 0.08 0.08 0.09

Competitive Comparison of HLS Therapeutics's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Asset Turnover falls into.


';

HLS Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

HLS Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=56.619/( (209.06+159.904)/ 2 )
=56.619/184.482
=0.31

HLS Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=15.542/( (171.74+159.904)/ 2 )
=15.542/165.822
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


HLS Therapeutics  (OTCPK:HLTRF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

HLS Therapeutics's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-12.092/75.335
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-12.092 / 62.168)*(62.168 / 165.822)*(165.822/ 75.335)
=Net Margin %*Asset Turnover*Equity Multiplier
=-19.45 %*0.3749*2.2011
=ROA %*Equity Multiplier
=-7.29 %*2.2011
=-16.05 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

HLS Therapeutics's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-12.092/165.822
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-12.092 / 62.168)*(62.168 / 165.822)
=Net Margin %*Asset Turnover
=-19.45 %*0.3749
=-7.29 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


HLS Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

HLS Therapeutics Headlines